2019 saw a major milestone year for Sesen Bio (SESN) with Type C CMC Meeting, Type B clinical pre-bla meeting, Type C confirmatory trial meeting, Type B cmc pre-bla meeting, obtaining small business exemption and starting the BLA submission under rolling review. Outside of the large spike in May-June 2019 from the announcement on Vicinium, the stock has continued to remain flat largely lagging under its amazing potential. On the verge of FDA approval, investors remain weary and are waiting to invest with concerns of continued dilution and lingering potential for the FDA